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Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting
side effect of anti-cancer therapies. CIPN symptoms include numbness in hands and feed,
shooting and burning pain in arms and legs, and muscle weakness, which can extend
beyond the time of treatment and may cause permanent disability. Many CIPNs are
primarily characterized by axon dysfunction and/or degeneration. Recent work from the
laboratories of Jeffrey Milbrandt and Aaron DiAntonio has shown the protective effect of
the genetic deletion of SARM1 (sterile alpha and TIF motif containing protein 1) on acute
axon degeneration (AxD). In axotomy experiments, SARM1 is regulated by the activation
of a MAP kinase cascade and acts through the decrease of NAD+. However, CIPN causes
subacute/chronic axonal loss, so it may work through a different pathway than acute injury
by axotomy. To gain insight into mechanisms of axonal loss in CIPN, we use the
chemotherapy drug vincristine to induce AxD in murine dorsal rot ganglia cultures. We
evaluated the effectiveness of drugs that disrupt the SARM1 pathway in axotomy to
examine if vincristine acts through a similar SARM1-mediated AxD pathway following
vincristine. We show that there is a significant decrease of vincristine-induced AxD with
the treatment of NR, and there is additional protection with a combination of NR and
JNKi, consistent with previous research on the protective effect of MAPK inhibitors and
NAD+ precursors in delaying acute AxD. This suggests that drugs that disrupt the SARM1
pathway can be therapeutic in delaying chronic axonal injury induced by vincristine, and
potentially other CIPNs.
